Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression

NCT06227325 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

27

Enrollment

OTHER_GOV

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: RC48 combined with Sintilimab and XELOX

Sponsor

Henan Cancer Hospital